Joint opinion of professional societies on pharmacological treatment of obesity

Česká verzia

Authors: Müllerová D. ¹; Haluzík M. ²; Sucharda P. ³; Boženský J. ⁴; Hainer V. ⁵; Holéczy P. ⁴; Kunešová M. ⁵; Málková I. ⁶; Slabá Š. ⁷; Šrámková P. ⁸; Taxová-Braunerová R. ⁵; Fried M. ⁸
Authors place of work: LF UK a FN Plzeň ¹; Institut klinické a experimentální medicíny, Praha ²; 1. LF UK a VFN v Praze ³; Nemocnice AGEL Ostrava-Vítkovice a. s. ⁴; Endokrinologický ústav, Praha ⁵; STOB, Praha ⁶; VFN v Praze ⁷; OB klinika, a. s., Praha ⁸
Published in the journal: Gastroent Hepatol 2020; 74(6): 499-512
Category:
doi: https://doi.org/10.48095/ccgh2020499

Summary

České obezitologické společnosti ČLS JEP, Společné sekce bariatricko-metabolické chirurgie České asociace preventivní kardiologie České společnosti pro aterosklerózu České diabetologické společnosti

Zdroje

1. König HH, Lehnert T, Brenner H et al. Health service use and costs associated with excess weight in older adults in Germany. Age Ageing 2015; 44 (4): 616–623. doi: 10.1093/ageing/afu120.

2. Specchia ML, Veneziano MA, Cadeddu C et al. Economic impact of adult obesity on health systems: a systematic review. Eur J Public Health 2015; 25 (2): 255–262. doi: 10.1093/eurpub/cku170.

3. Tremmel M, Gerdtham UG, Nilsson PM et al. Economic burden of obesity: a systematic literature review. Int J Environ Res Public Health 2017; 14 (4): 435. doi: 10.3390/ijerph14040435.

4. Flegal KM, Panagiotou OA, Graubard BI. Estimating population attributable fractions to quantify the health burden of obesity. Ann Epidemiol 2015; 25 (3): 201–207. doi: 10.1016/j.annepidem.2014.11.010.

5. Hebebrand J, Holm JC, Woodward E et al. A proposal of the European association for the study of obesity to improve the ICD-11 dia gnostic criteria for obesity based on the three dimensions etiology, degree of adiposity and health risk. Obes Facts 2017; 10 (4): 284–307. doi: 10.1159/000479208.

6. Yumuk V, Tsigos C, Fried M et al. European guidelines for obesity management in adults. Obes Facts 2015; 8 (6): 402–424. doi: 10.1159/000442721.

7. Greenway FL. Physiological adaptations to weight loss and factors favouring weight regain. Int J Obes (Lond) 2015; 39 (8): 1188–1196. doi: 10.1038/ijo.2015.59.

8. Sumithran P, Prendergast LA, Delbridge E et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 2011; 365 (17): 1597–1604. doi: 10.1056/NEJMoa1105816.

9. Jensen MD, Ryan DH, Apovian CM et al. 2013 AHA/ACC/TOS guideline for the mana gement of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 2014; 63 (25 Pt B): 2985–3023. doi: 10.1016/j.jacc.2013.11.004.

10. Lean ME, Leslie WS, Barnes AC et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018; 391 (10120): 541–551. doi: 10.1016/S0140-6736 (17) 33102-1.

11. Schutz DD, Busetto L, Dicker D et al. European practical and patient-centred guidelines for adult obesity management in primary care. Obes Facts 2019; 12 (1): 40–66. doi: 10.1159/000496183.

12. Wadden TA, West DS, Neiberg RH et al. One-year weight losses in the Look AHEAD study: factors associated with success. Obesity (Silver Spring) 2009; 17 (4): 713–722. doi: 10.1038/oby.2008.637.

13. Hainer V. Základy klinické obezitologie. Praha: Grada 2011.

14. Sjöström L, Rissanen A, Andersen T et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998; 352 (9123): 167–172. doi: 10.1016/s0140-6736 (97) 11509-4.

15. Leblanc ES, O’Connor E, Whitlock EP et al. Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155 (7): 434–447. doi: 10.7326/0003-4819-155-7-201110040-00006.

16. Torgerson JS, Hauptman J, Boldrin MN et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27 (1): 155–161. doi: 10.2337/diacare.27.1.155.

17. Davidson MH, Hauptman J, DiGirolamo M et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281 (3): 235–242. doi: 10.1001/jama.281.3.235.

18. Kelley DE, Bray GA, Pi-Sunyer FX et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care 2002; 25 (6): 1033–1041. doi: 10.2337/diacare.25.6.1033.

19. Tonstad S, Pometta D, Erkelens DW et al. The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol 1994; 46 (5): 405–410. doi: 10.1007/BF00191901.

20. Hvizdos KM, Markham A. Orlistat: a review of its use in the management of obesity. Drugs 1999; 58 (4): 743–760. doi: 10.2165/00003495-19995804 0-00015.

21. McNeely W, Benfield P. Orlistat. Drugs 1998; 56 (2): 241–250. doi: 10.2165/00003495-19985 6020-00007.

22. Greig SL, Keating GM. Naltrexone ER/Bupropion ER: a review in obesity management. Drugs 2015; 75 (11): 1269–1280. doi: 10.1007/ s40265-015-0427-5.

23. Caixàs A, Albert L, Capel I et al. Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. Drug Des Devel Ther 2014; 8: 1419–1427. doi: 10.2147/DDDT.S55587.

24. Greenway FL, Dunayevich E, Tollefson G et al. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab 2009; 94 (12): 4898–4906. doi: 10.1210/jc.2009-1350.

25. Hollander P, Gupta AK, Plodkowski R et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013; 36 (12): 4022–4029. doi: 10.2337/dc13-0234.

26. Wadden TA, Foreyt JP, Foster GD et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 2011; 19 (1): 110–120. doi: 10.1038/oby.2010.147.

27. Nissen SE, Wolski KE, Prcela L et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA 2016; 315 (10): 990–1004. doi: 10.1001/jama.2016.1558.

28. Bode B. An overview of the pharmacokinetics, efficacy and safety of liraglutide. Diabetes Res Clin Pract 2012; 97 (1): 27–42. doi: 10.1016/j.diabres.2011.12.015.

29. Jacobsen LV, Flint A, Olsen AK et al. Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2016; 55 (6): 657–672. doi: 10.1007/s40262-015-0343-6.

30. van Can J, Sloth B, Jensen CB et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond) 2014; 38 (6): 784–793. doi: 10.1038/ijo.2013.162.

31. Flint A, Kapitza C, Hindsberger C et al. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Adv Ther 2011; 28 (3): 213–226. doi: 10.1007/s12325-010-0110-x.

32. Horowitz M, Flint A, Jones KL et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract 2012; 97 (2): 258–266. doi: 10.1016/j.diabres.2012.02.016.

33. Pi-Sunyer X, Astrup A, Fujioka K et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015; 373 (1): 11–22. doi: 10.1056/NEJMoa1411 892.

34. le Roux CW, Astrup A, Fujioka K et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 2017; 389 (10077): 1399–1409. doi: 10.1016/S0140-6736 (17) 30069-7.

35. Davies MJ, D‘Alessio DA, Fradkin J et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Dia Care 2018; 41 (12): 2669–2701. doi: 10.2337/dci18-0033.

36. Wadden TA, Hollander P, Klein S et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. Int J Obes (Lond) 2015; 39 (1): 187. doi: 10.1038/ijo.2014.88.

37. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 1999; 22 (5): 667–689.

38. Marso SP, Daniels GH, Brown-Frandsen K et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375 (4): 311–322. doi: 10.1056/NEJMoa1603827.

39. Bays H, Pi-Sunyer X, Hemmingsson JU et al. Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects. Curr Med Res Opin 2017; 33 (2): 225–229. doi: 10.1080/03007995.2016.1251892.

40. Kolotkin RL, Fujioka K, Wolden ML et al. Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clin Obes 2016; 6 (4): 233–242. doi: 10.1111/cob.12146.

41. Blackman A, Foster GD, Zammit G et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial. Int J Obes (Lond) 2016; 40 (8): 1310–1319. doi: 10.1038/ijo.2016.52.

42. Fujioka K, O‘neil PM, Davies M et al. Early weight loss with liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in cinical markers. Obesity (Silver Spring) 2016; 24 (11): 2278–2288. doi: 10.1002/oby.21629.

43. Wadden TA, Walsh OA, Berkowitz RI et al. Intensive behavioral therapy for obesity combined with liraglutide 3.0 mg: a randomized controlled trial. Obesity (Silver Spring) 2019; 27 (1): 75–86. doi: 10.1002/oby.22359.

44. Modi R, Rye P, Cawsey et al. Liraglutide effects on upper gastrointestinal investigations: implications prior to bariatric surgery. Obes Surg2018; 28 (7): 2113–2116. doi: 10.1007/s11695-018-3249-1.

45. Suliman M, Buckley A, Tikriti AA et al. Routine clinical use of liraglutide 3 mg for the treatment of obesity: outcomes in non‐surgical and bariatric surgery patients. Diabetes Obes Metab 2019; 21 (6): 1498–1501. doi: 10.1111/dom.13672.

46. Garvey WT, Mechanick JI, Brett EM et al. American association of clinical endocrinologists and american college of endocrinology comprehensive clinical practice guidelines for mediccal care of patients with obesity. Endocr Pract 2016; 22 (Suppl 3): 1–203. doi: 10.4158/EP1613 65.GL.